Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome
Launched by CHONNAM NATIONAL UNIVERSITY HOSPITAL · May 15, 2015
Trial Information
Current as of May 09, 2025
Unknown status
Keywords
ClinConnect Summary
About 1400 patients derived from Korean patients with acute coronary syndrome (ACS) receiving percutaneous coronary intervention (PCI) with BES(Biolimus-eluting stent, BiomatrixTM) in a routine manner will be enrolled in the investigators trial.
These patients will be randomized 1:1 to either prasugrel 5mg once daily MD or clopidogrel 75mg once daily MD after successful PCI with BES .
The investigators excluded the patients with age ≥75 years, body weight \<60 kg, or history of TIA (transient ischemic attack) or stroke. Follow-up data will be collected until 1-year after index procedure.
...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients who can undergo percutaneous coronary intervention with Biomatrix stent with no history of TIA or stroke,
- • 75 years old or younger,
- • body weight of 60 kg or more and diagnosed with acute coronary syndrome
- Exclusion Criteria:
- • Patients with history of TIA or stroke,
- • 75 years old or older,
- • body weight of 60 kg or under,
- • hypersensitivity to or contraindicated for heparin, aspirin, clopidogrel, prasugrel or contrast media
About Chonnam National University Hospital
Chonnam National University Hospital, a leading medical institution in South Korea, is at the forefront of clinical research and innovation. As a sponsor of clinical trials, the hospital leverages its robust academic resources and multidisciplinary expertise to advance medical knowledge and improve patient care. With a commitment to ethical standards and patient safety, Chonnam National University Hospital collaborates with various stakeholders in the healthcare community to conduct rigorous studies that explore new therapies and treatment modalities. Its state-of-the-art facilities and dedicated research teams contribute to the successful execution of trials across a wide range of medical disciplines.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pusan, , Korea, Republic Of
Patients applied
Trial Officials
Myung Ho Jeong, PhD
Principal Investigator
Chonnam National University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials